Advertisement
ALNY vs BMY
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Bristol-Myers Squibb (BMY) Stock Comparison
Key Takeaways
- ALNY boasts strong YTD gains of approximately 23%, driven by robust revenue growth in RNAi therapeutics like AMVUTTRA, contrasting BMY's more modest 7% YTD rise amid oncology expansions.
- ALNY reported 81% full-year 2025 net product revenue growth to nearly $3 billion, with 2026 guidance projecting 71% growth, highlighting high-momentum biotech growth versus BMY's stable but slower legacy portfolio.
- Recent collaborations, such as ALNY's ATTR-CM partnership with Viz.ai and BMY's Opdivo label expansions, signal positive sentiment shifts in specialized therapies.
- BMY offers a 4.4% dividend yield and lower volatility (beta 0.30), appealing for stability-focused investors compared to ALNY's higher-risk profile (beta 0.87).
- Market caps differ markedly: ALNY at $40.7B reflects biotech premium, while BMY's $116B underscores diversified pharma scale.
- Both stocks show recent pullbacks, with ALNY down 6% monthly and BMY down 6-7%, amid broader sector pressures.
Introduction
This stock comparison between ALNY and BMY examines two biopharma leaders navigating distinct paths in the healthcare sector. Alnylam Pharmaceuticals (ALNY), a pioneer in RNA interference (RNAi) therapeutics, targets rare genetic diseases with high-growth potential, while Bristol-Myers Squibb (BMY) leverages a broad portfolio in oncology, immunology, and cardiology for steady revenue. Traders seeking momentum and pipeline catalysts may favor ALNY, whereas long-term investors prioritizing dividends and diversification might lean toward BMY. In the current market, relative performance highlights growth versus stability trade-offs amid regulatory wins and earnings momentum.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY) specializes in RNAi-based therapeutics for rare diseases, with marketed products including AMVUTTRA and ONPATTRO for ATTR amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. In recent market activity, ALNY shares have traded around $307, within a 52-week range of $206 to $496, reflecting volatility tied to clinical milestones. Year-to-date gains near 23% outpace broader indices, fueled by full-year 2025 net product revenues of $2.99 billion, up 81% year-over-year, primarily from TTR franchise growth. Sentiment has been bolstered by strategic collaborations like the Viz.ai partnership for ATTR-CM care advancement and a $250 million manufacturing investment. However, recent weeks saw a roughly 6% pullback amid analyst adjustments and pipeline execution risks, with 2026 guidance targeting $4.9-5.3 billion in revenues underscoring sustained momentum.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) is a global biopharma giant focused on oncology, hematology, immunology, and cardiovascular therapies, featuring blockbusters like Opdivo, Eliquis, and Revlimid alongside newer assets such as Breyanzi and Camzyos. Shares recently hovered near $57, in a 52-week band of $43 to $63, with year-to-date appreciation of about 7% supported by steady growth portfolio performance. Recent developments include FDA and EU approvals expanding Opdivo for classical Hodgkin lymphoma, enhancing its oncology dominance, and new data presented at the 2026 ACC conference reinforcing Camzyos in obstructive HCM. Earnings momentum from Q4 2025 showed growth products up 15%, though legacy declines pressured overall results. Shares dipped around 6% in recent weeks amid sector rotation, yet a 4.4% dividend yield and 2026 revenue guidance of $46-47.5 billion provide stability. Analyst targets averaging $63 suggest moderate upside potential.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top 25 AI trading bots from a library of 351, selected for their suitability to prevailing market conditions in stocks, ETFs, and crypto. These bots deliver real-time signals via diverse strategies—ranging from trend-following and dip-buying to hedging in down markets—with performance stats including annualized returns of 15% to 126%, win rates from 56% to 89%, and profit factors up to 6.11. Timeframes vary from days to months, with drawdowns managed through TP/SL corridors (e.g., 3% TP/2% SL). They trade sectors like semiconductors (e.g., ASML, LRCX), oil & gas (XOM, CVX), and defense (LMT, RTX), accommodating aggressive growth or conservative plays. Explore these bots to align AI-driven insights with your portfolio in dynamic conditions.
Head-to-Head Comparison
ALNY and BMY operate in biopharma but diverge in models: ALNY's RNAi focus drives explosive growth in rare diseases, with 81% revenue surge versus BMY's diversified mix balancing oncology catalysts against patent cliffs. Recent momentum favors ALNY on YTD outperformance and TTR dominance, while BMY exhibits lower beta (0.30 vs. 0.87) and dividend appeal. Risk profiles contrast sharply—ALNY faces pipeline binary events amid high P/E (136), BMY contends with legacy erosion but boasts scale. Sector exposure tilts ALNY toward innovative genetics, BMY toward immuno-oncology; sentiment leans positive for both on approvals, yet ALNY's catalysts imply higher volatility trade-offs.
Tickeron AI Verdict
Tickeron’s AI currently favors ALNY for traders eyeing relative strength, given superior trend consistency in recent revenue beats, AMVUTTRA momentum, and partnerships positioning it ahead in biotech growth. BMY suits conservative positioning with stability and yield, but ALNY's catalysts suggest higher probabilistic upside in the near term, barring execution risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and BMY is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileBMY’s FA Score has 2 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- BMY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 3 TA indicator(s) are bullish while BMY’s TA Score has 4 bullish TA indicator(s).
- ALNY’s TA Score: 3 bullish, 5 bearish.
- BMY’s TA Score: 4 bullish, 6 bearish.
Price Growth
ALNY (@Biotechnology) experienced а +1.02% price change this week, while BMY (@Pharmaceuticals: Major) price change was -1.64% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.86%. For the same industry, the average monthly price growth was -2.62%, and the average quarterly price growth was +6.54%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
BMY is expected to report earnings on Apr 30, 2026.
Industries' Descriptions
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (-0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ALNY | BMY | ALNY / BMY | |
| Capitalization | 43B | 120B | 36% |
| EBITDA | 631M | 15.2B | 4% |
| Gain YTD | -18.997 | 11.094 | -171% |
| P/E Ratio | 138.24 | 16.94 | 816% |
| Revenue | 3.71B | 48.2B | 8% |
| Total Cash | 2.91B | N/A | - |
| Total Debt | 1.28B | 47.1B | 3% |
ALNY | BMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 50 | 80 | |
SMR RATING 1..100 | 15 | 23 | |
PRICE GROWTH RATING 1..100 | 62 | 46 | |
P/E GROWTH RATING 1..100 | 100 | 68 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (5) in the Pharmaceuticals Major industry is significantly better than the same rating for ALNY (94) in the Biotechnology industry. This means that BMY’s stock grew significantly faster than ALNY’s over the last 12 months.
ALNY's Profit vs Risk Rating (50) in the Biotechnology industry is in the same range as BMY (80) in the Pharmaceuticals Major industry. This means that ALNY’s stock grew similarly to BMY’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is in the same range as BMY (23) in the Pharmaceuticals Major industry. This means that ALNY’s stock grew similarly to BMY’s over the last 12 months.
BMY's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as ALNY (62) in the Biotechnology industry. This means that BMY’s stock grew similarly to ALNY’s over the last 12 months.
BMY's P/E Growth Rating (68) in the Pharmaceuticals Major industry is in the same range as ALNY (100) in the Biotechnology industry. This means that BMY’s stock grew similarly to ALNY’s over the last 12 months.
| ALNY | BMY | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 59% |
| Stochastic ODDS (%) | 1 day ago 59% | 1 day ago 52% |
| Momentum ODDS (%) | 1 day ago 66% | 1 day ago 53% |
| MACD ODDS (%) | 1 day ago 68% | 1 day ago 56% |
| TrendWeek ODDS (%) | 1 day ago 71% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 69% | 1 day ago 56% |
| Advances ODDS (%) | 18 days ago 76% | 3 days ago 53% |
| Declines ODDS (%) | 10 days ago 66% | 5 days ago 53% |
| BollingerBands ODDS (%) | 1 day ago 73% | 1 day ago 57% |
| Aroon ODDS (%) | 1 day ago 78% | 1 day ago 54% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PSCE | 59.04 | 0.12 | +0.20% |
| Invesco S&P SmallCap Energy ETF | |||
| LAPR | 25.28 | N/A | N/A |
| Innovator Premium Inc 15 Bffr ETF - Aprl | |||
| JMST | 50.91 | -0.01 | -0.01% |
| JPMorgan Ultra-Short Municipal Inc ETF | |||
| GHY | 11.75 | -0.05 | -0.42% |
| PGIM Global High Yield Fund | |||
| CCFE | 27.02 | -0.21 | -0.79% |
| Concourse Capital Focused Equity ETF | |||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been closely correlated with PFE. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | -1.43% | ||
| PFE - BMY | 67% Closely correlated | -1.10% | ||
| MRK - BMY | 63% Loosely correlated | -1.03% | ||
| ABBV - BMY | 58% Loosely correlated | -2.10% | ||
| AMGN - BMY | 58% Loosely correlated | -1.29% | ||
| BIIB - BMY | 54% Loosely correlated | -2.34% | ||
More | ||||